MedTrace Logo

Allele-specific Expression of a Bitter Taste Receptor

NCT02766959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2018-09-18

No results posted yet for this study

Summary

This single-site, within-subject experimental basic research study is designed to analyze the hypothesis that allele-specific expression of the bitter taste receptor T2R38 in taste tissue of individuals heterozygous for the taste receptor gene TAS2R38 correlates with that in nasal epithelium, and is responsible for differences in acyl-homoserine lactone-induced respiratory defenses. Subjects will include 100 predominantly European adults without chronic rhinosinusitis who will be undergoing a sinonasal procedure for reconstructive purposes. All subjects will provide saliva samples for genotyping, from which 25 subjects heterozygous for TAS2R38 (AVI/PAV) will be identified. These individuals will be asked to complete a beverage frequency questionnaire and taste test prior to the procedure that will evaluate for a number of compounds, among them bitter ligands specific to T2R38. Their tongue will also be photographed to evaluate the anatomy of their fungiform papillae, the mushroom-like structures on the tongue which contain taste buds. Subjects will subsequently provide nasal epithelium and taste tissue, which will be processed to 1) evaluate for allele-specific expression of TAS2R38 mRNA in both the taste and nasal tissue, with the nasal tissue concurrently being cultured in an air-liquid interface system to 2) assess the AHL-induced respiratory defenses of ciliary beat frequency (CBF) and nitric oxide (NO) production. Should subjects require a subsequent sinonasal procedure for clinically-determined reasons, taste and nasal tissue will again be obtained and analyzed for TAS2R38 mRNA, allowing for 3) longitudinal evaluation of mRNA expression level.

Conditions

  • Rhinosinusitis

Interventions

OTHER

Observational study

Sponsors & Collaborators

  • University of Pennsylvania

    collaborator OTHER

  • Corporal Michael J. Crescenz VA Medical Center

    collaborator FED

  • Monell Chemical Senses Center

    lead OTHER

Principal Investigators

  • Danielle R. Reed, Ph.D. · Monell Chemical Senses Center

  • Noam A. Cohen, M.D., Ph.D. · Monell Chemical Senses Center, University of Pennsylvania

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766959 on ClinicalTrials.gov